Variant Bio turns focus from identifying genomic variants to drug discovery
Seattle-based biotech company Variant Bio will be creating new therapeutic programs to enhance its current research on genomic variants. The addition of Dr. David Moller and Dr. Steve Bryant to Variant Bio’s team will help the company expand its abilities and offerings.
Variant Bio studies genetics to find connections between biological abnormalities and disease. Moller and Bryant, who will serve as chief scientific officer and chief business officer respectively, will provide Variant Bio with resources to turn these findings into tangible therapies that can help patients who struggle with certain illnesses and diseases.
“I’m deeply excited to add David and Steve, with their complementary experience and expertise, to our talented team,” said CEO Andrew Farnum.